Princeton-based Soligenix gets FDA boost for drug to treat chemotherapy side effect

 

Alexi Friedman/The Star-Ledger By Alexi Friedman/The Star-Ledger

The Star-Ledger Email the author | Follow on Twitter on June 03, 2013 at  6:00 PM, updated June 03, 2013 at  6:22 PM

Princeton-based Soligenix is developing a drug to treat a painful inflammation found in patients who undergo radiation therapy for head and neck cancer.Soligenix

More than 80 percent of patients who undergo radiation therapy for throat, nose and mouth cancer develop a painful tissue swelling that can lead to infection. Nearly half of the people who receive chemotherapy for the same diseases are also affected.
Continue reading

Advertisements

Tags: ,

Categories: Life Sciences Industry Network

Author:NJ Tech Council

The New Jersey Tech Council helps companies grow and supports the tech, innovation and entrepreneurial ecosystems in the state and region.

NJTC TechWire

Daily updates about the region's most tech savvy companies

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s